Non-Muscle Invasive Bladder Cancer VL

BCG Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer - Seth Lerner

Details
Alicia Morgans is joined by Seth Lerner and discuss his State-of-the-Art Lecture on Bacillus Calmette–Guérin (BCG) unresponsive disease in non-muscle-invasive bladder cancer. They discuss the FDA’s guidance in terms of clinical trial design in the BCG-unresponsive disease space and recap where the treatment landscape is now and what is on the horizon as far as molecular subtypes and predictive bio...

Demonstrated Underuse of Blue Light Cystoscopy for Bladder Cancer in the United States - Patrick Lewicki

Details
Ashish Kamat is joined by Patrick Lewicki to discuss the recent publication on the underutilization of Blue Light Cystoscopy (BLC) in the United States. Studying the use of BLC in the Premier Healthcare Database, the findings demonstrate a low level of BLC use despite guideline recommendations and evidence demonstrating the benefit for its use in the management of non-muscle invasive bladder cance...

The Association of Smoking Status with Recurrence in Patients with Predominantly High-Risk Recurrent NMIBC - Richard Matulewicz

Details
Richard Matulewicz joins Ashish Kamat presenting findings on the association of smoking status on recurrence of non-muscle invasive bladder cancer (NMIBC) in a contemporary cohort of patients with predominantly high-risk, recurrent NMIBC managed with photodynamic enhanced cystoscopy. A retrospective study was conducted in a multi-institutional registry. Smoking has a strong causal association with...

The Natural History of High-Risk NMIBC: Novel Therapies vs Cystectomy - Angela Smith

Details
Ashish Kamat welcomes Angela Smith to discuss high-risk non-muscle-invasive bladder cancer, particularly cases unresponsive to BCG treatments. Dr. Smith explores the complexities of decision-making, emphasizing the importance of a multidisciplinary approach with new therapies like pembrolizumab, nadofaragene, and oportuzumab. She also outlines an observational trial she is leading, aimed at compar...

The Role of Radiology and Radiomics in Staging & Risk Stratification of NMIBC - Manjiri Dighe

Details
Ashish Kamat hosts Manjiri Dighe for a discussion on the evolving role of radiology in bladder cancer diagnosis and staging. Dr. Dighe elaborates on the limitations and advancements in imaging techniques like CT scans, MRI, and ultrasound, emphasizing their increasing importance for assessing local tumor invasion and lymph node spread. The conversation also delves into the potential of newer metho...

Novel Immune Checkpoint Axis To Understand BCG Resistance and Improve Treatment in Non-muscle Invasive Bladder Cancer - Amir Horowitz & John Sfakianos

Details
John Sfakianos and Amir Horowitz join Ashish Kamat discussing a novel immune checkpoint axis in non-muscle-invasive bladder cancer, specifically looking at the HLA-E and NKG2A axis in non-muscle invasive bladder cancer, as it relates to Bacillus Calmette-Guerin (BCG) and BCG resistance. Biographies: Amir Horowitz, Ph.D., is an Assistant Professor of Oncological Sciences and a member of the Precisi...

Conundrums in Bacillus Calmette Guerin (BCG) Unresponsive Nonmuscle Invasive Bladder Cancer Trials - Roger Li

Details
Joining Ashish Kamat from the Moffit Cancer Center in Tampa, Florida is Roger Li to dive into all things BCG unresponsive bladder cancer. Dr. Li shares what is known about BCG unresponsive disease, some of the conundrums that clinicians and the FDA are challenged by when evaluating and designing clinical trials in this area, and answers a series of questions from Dr. Kamat covering many topics in...

Combining BCG and Intravesical Gemcitabine (GBIG) for Patients with BCG-Relapsing High-Grade NMIBC Cancer A Phase 1/2 Trial- Eugene Pietzak

Details
Eugene Pietzak, MD joins Ashish Kamat, MD MBBS, to discuss an investigator-initiated trial, "Combination BCG and Intravesical Gemcitabine (CBIG) in Patients with BCG Relapsing Non-Muscle Invasive Bladder Cancer" (NCT04179162) that is currently recruiting. Dr. Pietzak explains the rationale for the trial design and the background on the questions this trial seeks to understand, in the combination o...

The Use of Blue Light Cystoscopy for Both Hospital and Outpatient Clinic - Yair Lotan and Daniel Parker

Details
Yair Lotan, MD, and Daniel Parker, MD join Ashish Kamat, MD, MBBS in a discussion on the efficacy and utilization of Blue Light Cystoscopy (BLC) Cysview® (hexaminolevulinate HCl). Dr. Lotanoffers his perspective on the use of blue light cystoscopy in bladder cancer detection in the hospital and Dr. Parker offers his perspective on the use in the office. Studies have shown that BLC improves the det...

Improved Tumor Visibility, Detection Rate and Reduced Recurrence Rates After TURBT - Siamak Daneshmand and Marek Babjuk

Details
Siamak Daneshmand and Marek Babjuk join Ashish Kamat in this conversation on improving tumor detection through improved visibility and reducing recurrence rates of bladder cancer. Siamak Daneshmand offers his perspective on the use of Blue Light Cystoscopy (BLC®) with Cysview® for improving detection and reduced recurrence of bladder cancer. Marek Babjuk presents his perspective on the use of phot...